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Abstract Background: Empiric treatment of complicated intra-abdominal infec-
tions (cIAI) represents a clinical challenge because of the diverse bacteriology and
the emergence of bacterial resistance. The efficacy and safety of tigecycline (TGC),
a first-in-class, expanded broad-spectrum glycylcycline antibiotic, were compared
with imipenem/cilastatin (IMI/CIS) in patients with cIAI.
Methods: In this prospective, double-blind, phase 3, multinational trial, patients
were randomly assigned to intravenous (IV) TGC (100 mg initial dose, then 50 mg
every 12 h) or IV IMI/CIS (500/500 mg every 6 h) for 5e14 days. Clinical response
was assessed at the test-of-cure (TOC) visit (14e35 days after therapy) for
microbiologically evaluable (ME) and microbiologically modified intent-to-treat
(m-mITT) populations (co-primary efficacy endpoint populations in which cure/
failure response rates were determined).
Results: Of 817 mITT patients (i.e., receivedR 1 dose of study drug), 641 (78%)
comprised the m-mITT cohort (322 TGC, 319 IMI/CIS) and 523 (64%) were ME (266
TGC, 256 IMI/CIS). Patients were predominantly white (88%) and male (59%) with
a mean age of 49 years. The primary diagnoses for the mITT group were
complicated appendicitis (41%), cholecystitis (22%), and intra-abdominal abscess
(11%). For the ME population, clinical cure rates at TOC were 91.3% (242/265) for
TGC versus 89.9% (232/258) for IMI/CIS (95% CI 4.0, 6.8; P! 0.001). Correspond-
ing clinical cure rates within the m-mITT population were 86.6% (279/322) for TGC
versus 84.6% (270/319) for IMI/CIS (95% CI 3.7, 7.5; P! 0.001 for noninferiority
TGC versus IMI/CIS). The most commonly reported adverse events for TGC and IMI/
CIS were nausea (17.6% TGC versus 13.3% IMI/CIS; PZ 0.100) and vomiting (12.6%
TGC versus 9.2% IMI/CIS; PZ 0.144).
Conclusions: TGC is efficacious in the treatment of patients with cIAIs and TGC met
per the protocol-specified statistical criteria for noninferiority to the comparator,
IMI/CIS.
ª 2005 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.Introduction
Intra-abdominal infections encompass a broad va-
riety of pathological conditions ranging from a lo-
calized infection to multi-system organ failure.
These infections are most often categorized as
a primary infection of the peritoneal space (i.e.,
spontaneous bacterial peritonitis), infection con-
tained within the site of origin (i.e., simple
appendicitis, cholecystitis), infection due to
breach of the bowel wall (i.e., perforated appen-
dicitis), or a secondary infection of the peritoneal
cavity due to penetrating injuries or surgical
procedures, and abscesses of the solid intra-
abdominal organs (i.e., liver abscess). Complicated
intra-abdominal infections are specifically defined
as secondary infections that extend through a phys-
ical hole in the gastrointestinal tract or through
a necrotic gut wall into the peritoneal space
leading to abscess formation or peritonitis.1
The majority of complicated intra-abdominal
infections are polymicrobial, involving multiple
bacterial isolates that are normally present within
the gastrointestinal tract.2 Overall, Enterobacter-
iaceae are the most commonly isolated organisms(typically Escherichia coli); however, enterococci,
as well as anaerobes such as Bacteroides spp and
anaerobic streptococci, are usually present in
varying combinations and proportions.1,3 Although
isolation of enterococci from an intra-abdominal
source was once dismissed as indigenous flora,
these bacteria are now recognized as true patho-
gens, with approximately 14%e33% of cultures
yielding enterococci.2 Anaerobes are a common
etiology, especially when infection occurs beyond
the proximal ileum.1 Empiric antimicrobial treat-
ment of complicated intra-abdominal infections
must consider a broad array of potential bacteria.
Furthermore, the likelihood that the implicated
isolates may possess resistance factors (e.g.,
extended spectrum beta-lactamases [ESBLs]) that
convey antimicrobial resistance in some patients
(e.g., immunocompromised and ICU patients)
makes the selection of agents with activity against
a variety of potentially resistant isolates crucial
when choosing the optimal therapy.4 Adequate
source control must complement appropriate an-
timicrobial therapy in order to achieve the desired
outcome.1 There is also growing evidence that the
use of an inappropriate empiric antimicrobial
Tigecycline for complicated intra-abdominal infections 37regimen to treat intra-abdominal infections is
associated with a worse outcome and an increased
risk of mortality.5,6
Tigecycline is a novel, expanded broad-spec-
trum, glycylcycline antibiotic with in vitro activity
against aerobic and facultative gram-positive and
gram-negative bacteria and anaerobic bacteria
typically implicated as causes of complicated
intra-abdominal infections.7e10 Of relevance to
intra-abdominal infections, tigecycline also pro-
vides activity against antibiotic-resistant bacteria
such as vancomycin-resistant Enterococcus faeca-
lis, extended-spectrum beta-lactamase-producing
enteric gram-negative bacteria, and methicillin-
resistant Staphylococcus aureus.7e15 The primary
purpose of the current trial was to assess the
efficacy and safety of tigecycline monotherapy
compared with imipenem/cilastatin in the treat-
ment of hospitalized adult patients with compli-
cated intra-abdominal infections. This study also
evaluated the in vitro susceptibility data of tige-
cycline against the range of bacteria present in
these infections.
Patients and methods
Study design and antimicrobial regimens
This was a phase 3, multicenter, double-blind
(third-party unblinded) trial of adult patients
who were candidates for or had undergone a lap-
arotomy, laparoscopy, or percutaneous drainage of
an intra-abdominal abscess and had a known or
suspected diagnosis of complicated intra-abdomi-
nal infections. The protocol was reviewed and
approved by the institutional review board or
ethical review committee at each participating
center. Written informed consent was obtained
from each patient or his or her legal representative
before the administration of any study procedures.
The trial was conducted in accordance with the
Declaration of Helsinki.
Patients were stratified at randomization into 2
groups based on their scores on the Acute Physio-
logic and Chronic Health Evaluation (APACHE) II:
%15, or O15 but !31. Using a 1:1 ratio, patients
were then assigned to receive tigecycline (initial
100-mg dose given by intravenous [IV] infusion over
a 30-min period, followed by 50 mg IV every 12 h)
or IV imipenem/cilastatin (500 mg/500 mg every
6 h or dose-adjusted based on weight and creati-
nine clearance) according to a randomization
schedule generated by the Wyeth Research Global
Biostatistics Technology department. A computer-
ized randomization and enrollment system ofautomatic telephonic randomization (CORE) was
used and provided access 24 h a day. After a pa-
tient was screened and deemed eligible for the
study, the unblinded dispenser (pharmacist or
accredited nurse) called the telephone number
provided to determine the treatment assignment.
If a randomization number was obtained from
CORE but not used (e.g., a patient was assigned
to treatment but did not receive the study drug),
the reuse of the randomization number was pro-
hibited. Unless the patient was a clinical failure
(see Section Clinical and bacteriologic assessments
and evaluation below), the duration of study drug
therapy ranged from 5 to 14 days.
Study drug was administered only when there
was a strong suspicion (i.e., elevated white blood
cell count, elevated band cell counts [‘‘shift to the
left’’], fever, or highly suggestive radiographic
findings) or a confirmed diagnosis of an intra-
abdominal infection (presence of pus within the
abdominal cavity). A baseline intra-abdominal cul-
ture was obtained from the site of infection in all
patients. Patients could be enrolled before drain-
age of the intra-abdominal infection and may have
received up to 2 doses of study drug before the
baseline cultures were obtained. Patients did not
receive more than 1 dose (or combination) of
parenteral nonstudy antibacterial drugs after the
baseline intra-abdominal cultures were obtained.
However, wound irrigation solutions of sterile water
or normal saline and topical antiseptics were
permitted throughout the course of the study.
Baseline aerobic and anaerobic cultures from
the primary intra-abdominal site of infection and 2
sets of blood cultures were obtained within 24 h of
the first dose of study drug. All aerobic and
anaerobic bacterial isolates, regardless of the
source of cultured material, were identified and
tested at a central laboratory (Covance Central
Laboratory Services, Inc., Indianapolis, IN, or
Geneva, Switzerland) by using a standard procedure
approved by the National Committee of Clinical
Laboratory Standards (NCCLS) Subcommittee on
Antimicrobial Susceptibility Testing. For tigecy-
cline, provisional minimum inhibitory concentration
(MIC) breakpoints were used (susceptible% 2 mg/L;
intermediate 4 mg/L; resistantR 8 mg/L).
Entry criteria
Hospitalized patients were eligible for inclusion if
they were at least 18 years of age and required
a surgical procedure for a complicated intra-
abdominal infection. Complicated intra-abdominal
infections included conditions such as an intra-
abdominal abscess (including liver and spleen) that
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standard antibacterial therapy; appendicitis com-
plicated by perforation and/or a periappendiceal
abscess; perforated diverticulitis complicated by
abscess formation or fecal contamination; compli-
cated cholecystitis with evidence of perforation,
empyema, or gangrene; perforation of the stom-
ach or duodenum for a period not to exceed 24 h;
or perforation of the large or small intestine for
a period longer than 12 h. In addition, patients
could not have received more than 1 dose of an
antibiotic (single broad-spectrum agent or 1 dose
of each antibiotic in a combination regimen such
as metronidazole, ampicillin, and gentamicin)
after the baseline intra-abdominal culture was
obtained from the infected site.
Patients were excluded for the following primary
reasons: pregnant or breastfeeding women; pre-
operative suspicion of a diagnosis of spontaneous
bacterial peritonitis, simple cholecystitis, gangre-
nous cholecystitis without rupture, simple appen-
dicitis, acute suppurative cholangitis, pancreatic
abscess, or infected necrotizing pancreatitis;
APACHE II score greater than 30; active or treated
leukemia or systemic malignancy or metastatic
malignancy to the abdomen; presence of any un-
controlled central nervous system disease, includ-
ing seizures; known or suspected hypersensitivity to
either study antibiotic or other compounds related
to the glycylcycline or carbapenem classes; pres-
ence of hepatic disease (i.e., aspartate aminotrans-
ferase [AST] or alanine aminotransferase
[ALT]O 10 times the upper limit of normal [ULN]
or total bilirubin valueO 3 times the ULN) or acute
hepatic failure or acute decompensation of chronic
hepatic failure; presence of renal disease, defined
as a calculated creatinine clearance! 41 mL/min/
1.73 m2 after adequate hydration; neutropenia
with absolute neutrophil count! 1000/mm3, with
counts as low as 500/mm3 permitted if due to the
acute infectious process; current intra-abdominal
infection known to be caused by one or more
bacterial isolates not likely to be susceptible to
both of the study drugs; surgical procedure re-
quiring that fascia or deep muscular layers be left
open or planned abdominal re-exploration; and
administration of intra-operative antibacterial irri-
gants or peritoneal antibacterial agents (e.g.,
irrigants, antibiotic-impregnated sponges).
Analysis populations
Several subpopulations of patients were assessed
for safety, clinical, and bacteriologic outcomes.
Patients who satisfied the inclusion/exclusion cri-
teria were included in the intent-to-treat (ITT)population, whereas the subset of patients who
received at least 1 dose of study drug made up the
modified intent-to-treat (mITT or safety) popula-
tion. Patients in the mITT population who had
clinical evidence of a complicated intra-abdominal
infection (clinically modified intent-to-treat
[c-mITT] population), by meeting the minimal
disease criteria, and had a confirmed baseline
isolate constituted the microbiologically modified
(m-mITT) population. From this latter group, the
microbiologically evaluable (ME) population was
defined as those who met all inclusion/exclusion
criteria or received an exemption before enroll-
ment in study; had at least 5 days of therapy; did
not receive concomitant antibiotics after the
baseline intra-abdominal culture was obtained
through the test-of-cure visit; had a test-of-cure
visit 14e35 days after the first dose of study drug;
and had a baseline intra-abdominal culture con-
taining at least 1 causative isolate that was
susceptible to both study drugs. If these criteria
were not met at any time during the study, the
patient was declared a clinical failure. Patients
were considered nonevaluable for inclusion in the
ME population if death occurred or if they with-
drew from the study! 48 h after the first dose of
study drug.
Clinical and bacteriologic assessments and
evaluation
Patients were evaluated at serial visits throughout
the study. The clinical response was determined by
the investigator and was defined at the test-of-cure
visit (14e35 days after therapy) as one of the
following: Cure e the course of study drug and the
initial intervention (operative and/or radiologically
guided drainage procedure) resolved the intra-
abdominal infectious process; Failuree the patient
had a lack of response during treatment and re-
quired additional antibacterial therapy other than
the study drug, or the initial recovery from the
infection was followed by deterioration before the
test-of-cure visit that required further antimicro-
bial therapy, the patient required additional surgi-
cal or radiologic intervention to cure the infection,
death due to infection occurred after 48 h of
therapy, or the patient received an extended
course of study drug (i.e., O120% of the planned
number of doses); and Indeterminate e the patient
was lost to follow-up (failure to have an outcome
determination), or died within 48 h after the first
dose of tigecycline for any reason, or died after 48 h
because of noninfectious-related reasons (as
judged by the investigator).
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abdominal culture, the susceptibilities of identi-
fied organisms, and the clinical outcome of the
patient, the investigator also evaluated the micro-
biologic response at the isolate and patient level
at the test-of-cure visit. The microbiologic
response by isolate for each baseline isolate
included: eradication, persistence, or indetermi-
nate. Microbiologic response by patient was cate-
gorized as eradication, persistence, superinfection
(i.e., the emergence of a new isolate was docu-
mented at the site of infection or at a distant site
with worsening signs and symptoms of infection),
and indeterminate. Microbiologic responses, by
isolate or patient, were often presumed and based
on clinical response (e.g., eradication in the case
of clinical cure) because no follow-up culture was
available.
Safety/tolerability assessments
Any patient who received at least 1 dose of study
drugwas included in the evaluation for safety (mITT
population). Safetywas assessed viamedical history
and physical examination findings, reports of clin-
ical adverse events, and findings from routine
electrocardiograms (ECGs), and serum chemistry,
hematology, coagulation, and urinalysis tests.
Adverse events were recorded throughout the study
period, up to and including the test-of-cure visit.
Before unblinding, the investigator categorized the
severity of each adverse event and the relationship
to study drug. Serious adverse events (i.e., those
that were life-threatening, led to prolongation of
the existing hospitalization, or caused persistent or
significant disability or incapacity, or death) were
also recorded.
Statistical analysis
Statistical analysis was performed by the Clinical
Biostatistics department of Wyeth Research, Col-
legeville, PA. The primary endpoints of the study
were clinical response at the test-of-cure visit
(14e35 days after therapy) for the ME and m-mITT
populations. Secondary analyses included bacteri-
ologic response at the test-of cure visit by patient
and isolate, as well as clinical response rates
stratified as monomicrobial versus polymicrobial,
and by isolate.
Categorical baseline demographic and medical
variables were analyzed using the Fisher exact
test. For continuous variables, a 1-way analysis of
variance (ANOVA) model was used to compare the
2 treatment groups. The difference betweentreatment groups in the percentage of premature
discontinuations from study drug was evaluated by
using a 2-sided Fisher exact test. Between-group
comparisons of adverse events were analyzed by
using the Fisher exact test.
The noninferiority of tigecycline compared with
imipenem/cilastatin was evaluated for clinical and
microbiologic responses by using a 2-sided 95%
confidence interval (CI) for the true difference in
efficacy (tigecycline minus imipenem/cilastatin)
adjusted for the stratification variable APACHE II
score and corrected for continuity. Noninferiority
was concluded if the lower limit of the 2-sided 95%
CI was greater than or equal to 15%. For all
subpopulation analyses (e.g.,monomicrobial versus
polymicrobial), an adjusted difference between
treatment groups with its 95% CI was calculated
from a generalized linear model with a binomial
probability function and an identity link.
By assuming an evaluability rate of at least 50%,
approximately 788 patients were to be randomly
assigned to obtain 394 ME patients. Based on the
assumption that the 2 treatments were equally
effective, with favorable clinical cure rates of 70%
at the test-of-cure assessment, 197 patients per
treatment group were required to ensure with 90%
probability (i.e., 90% power) that the lower limit of
a 1-sided 97.5% confidence interval for the true
difference (tigecycline minus imipenem/cilasta-
tin) does not exceed 0.15.
Results
Patient disposition and analysis populations
A total of 861 patients were screened for study
participation at 94 sites in 27 countries in Europe,
South Africa, Australia, and Asia from November
2002 to May 2004, of these, 37 failed to satisfy
protocol requirements (Fig. 1). The remaining 824
patients were randomly assigned to 1 of the 2
treatment regimens and constituted the ITT pop-
ulation, although 7 patients never received study
drug. As such, 817 patients constituted the mITT or
safety population (404 tigecycline, 413 imipenem/
cilastatin), with 794 patients exhibiting clinical
evidence of a complicated intra-abdominal infec-
tion (clinical mITT). Within this latter cohort, 690
patients were clinically evaluable (CE population)
and 641 patients had a pretherapy isolate recov-
ered and comprised the m-mITT population.
A total of 523 patients (265 tigecycline, 258
imipenem/cilastatin) met clinical evaluability cri-
teria and had a pretherapy isolate isolated from
an intra-abdominal source (ME population). The
40 P. Fomin et al.Figure 1 Patient disposition and analysis population.primary reasons for exclusion from the CE popula-
tion were no clinical evaluation at the test-of-cure
visit (nZ 33); entry criteria not met (nZ 31);
received concomitant antimicrobials (nZ 28);
blind broken (nZ 18); and did not receive re-
quired number of study drug doses (i.e., at least 8
doses for those who failed; nZ 16).
Demographic/baseline medical
characteristics
Overall, the mITT population was primarily white
(88%) men (59%) with a mean age of 49 years
(Table 1). Demographic characteristics were wellbalanced between the 2 treatments. The most
common intra-abdominal infection diagnoses were
complicated appendicitis (41%), followed by com-
plicated cholecystitis (22%) and intra-abdominal
abscess (11%). There were no significant differ-
ences between the treatment groups in the num-
ber or types of infections diagnosed at baseline.
The mITT patients received an average of 7e8 days
of antimicrobial treatment.
Clinical efficacy
Overall, clinical cure was reported for 86.6% of
tigecycline and 84.6% of imipenem/cilastatin
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Tigecycline (NZ 404) Imipenem/cilastatin (NZ 413)
MeanG SD age, years 48.3G 18.4 49.5G 18.0
Sex, n (%) male 239 (59.2) 240 (58.1)
Ethnic origin, n (%)
White 349 (86.4) 370 (89.6)
Black 12 (3.0) 13 (3.1)
Asian 29 (7.2) 23 (5.6)
Other 14 (3.5) 7 (1.7)
MeanG SD weight, kg 74.1G 14.9 74.5G 15.7
MeanG SD creatinine clearance, mL/min 99.7G 36.3 97.3G 30.6
MeanG SD therapy duration, days 7.7G 2.7 7.8G 2.7
Mean APACHE II score 6.44 6.41
Primary intra-abdominal diagnosis, n (%)
Complicated appendicitis 158 (41.6) 167 (40.4)
Complicated cholecystitis 80 (19.8) 98 (23.7)
Complicated diverticulitis 21 (5.2) 25 (6.1)
Intra-abdominal abscess 46 (11.4) 46 (11.1)
Peritonitis 9 (2.2) 7 (1.7)
Gastric/duodenal perforation 32 (7.9) 36 (8.7)
Perforation of intestine 42 (10.4) 31 (7.5)
Othera 6 (1.5) 3 (0.7)
a Other diagnoses included complicated salpingitis, pyosalpinx, tubo-ovarial abscess, peritonitis due to left pyo-ovarium (local
abscess), right and left purulent salpingitis, perforated suppurative left ovary cyst, intra-abdominal abscess after ovarian
cystectomy, acute salpingitis with purulent peritonitis, and septic incomplete abortion with traumatized uterus and perforation.
b All differences were not statistically significant (PO 0.05).recipients in the m-mITT population (95% CI 3.7,
7.5; Table 2). Corresponding clinical cure rates
for the ME population were 91.3% and 89.9% (95%
CI 4.0, 6.8). The results indicated that tigecy-
cline is efficacious for these 2 populations by
meeting statistical criteria for the noninferiority
compared with imipenem/cilastatin.
In addition, no significant treatment differences
in clinical response were observed between the 2
antimicrobial groups when patients were stratified
by number of pretherapy isolatesdmonomicrobial
versus polymicrobial (Table 2). For the ME popula-
tion, tigecycline was associated with 94.5% and
89.7% clinical cure rates at the test-of-cure visit
for monomicrobial versus polymicrobial infections,
respectively. Patients given imipenem/cilastatin
had similar clinical cure rates 92.2% and 88.7%,
respectively. In general, patients with polymicro-
bial intra-abdominal infection tended to have
lower clinical cure rates compared with those
who had infections due to a single isolate.
For complicated appendicitis, the most fre-
quent diagnosis, clinical cure at the test-of-cure
visit was nearly identical between the 2 treatment
groups: 93.7% for tigecycline versus 93.2% for
imipenem/cilastatin (Table 3). Similar clinical cure
rates were found for those with complicatedcholecystitis (98.2% tigecycline versus 96.6% imi-
penem/cilastatin). Patients in both treatment
groups with intra-abdominal abscess, complicated
diverticulitis, and intestinal perforation had lower
cure rates regardless of treatment assignment
(70%e85%; Table 3). Based on primary intra-
abdominal diagnosis, there were no significant
differences in clinical cure rates between tigecy-
cline and imipenem/cilastatin. A total of 26
tigecycline- and 23 imipenem/cilastatin-treated
patients had concomitant bacteremia. Clinical
cure in patients with bacteremia was reported
for 88.5% of tigecycline-treated and 87% of imipe-
nen/cilastatin-treated patients.
Microbiologic efficacy
For the ME population, eradication at the patient
level was reported for 91.3% of tigecycline and
89.9% of imipenem/cilastatin recipients (95%
CI 4.0, 6.8), indicating that tigecycline was non-
inferior to imipenem/cilastatin in eradicating com-
plicated intra-abdominal infections (Table 4). No
significant differences between the treatment
groups were discernable when eradication rates
were stratified by monomicrobial versus polymi-
crobial infection.
Test for
noninferiority,
P value
Test for
differences
!0.0001 0.9166
0.4 (4.1, 4.9)a
!0.0001 0.7806
0.9 (4.2, 6.0)a
!0.0001 0.6904
0.2 (4.0, 4.4)a
!0.0001 0.5406
2.2 (3.2, 7.6)a
tity link. CI, confidence interval; CE, clinically
ns); ME, microbiological evaluable; m-mITT,
Difference (tigecyclineeimipenem/
cilastatin), % (95% CI)
0.5 (7.1, 8.0)
2.7 (31.0, 34.7)
1.7 (7.6, 11.3)
3.2 (17.3, 24.9)
25.0 (39.9, 78.1)
13.3 (18.7, 41.6)
1.0 (21.8, 29.5)
50.0 (97.3, 43.1)
1.5 (20.5, 24.7)
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Tigecycline Imipenem/cilastatin Difference
(tigecyclineeimipenem/
cilastatin), % (95% CI)
n/N % (95% CI) n/N % (95% CI)
CE 312/344 90.7 (87.1, 93.6) 312/346 90.2 (86.5, 93.1) 0.5 (4.2, 5.2)
Overall
c-mITT 336/393 85.5 (81.6, 88.8) 339/401 84.5 (80.6, 87.9) 1.0 (4.3, 6.2)
Overall
ME 242/265 91.3 (87.3, 94.4) 232/258 89.9 (85.6, 93.3) 1.4 (4.0, 6.8)
Monomicrobial 86/91 94.5 (87.6, 98.2) 83/90 92.2 (84.6, 96.8) 2.3 (6.3, 11.1)
Polymicrobial 156/174 89.7 (84.1, 93.8) 149/168 88.7 (82.9, 93.1) 1.0 (6.1, 8.2)
Overall
m-mITT 279/322 86.6 (82.4, 90.2) 270/319 84.6 (80.2, 88.4) 2.0 (3.7, 7.5)
Monomicrobial 108/120 90.0 (83.2, 94.7) 102/119 85.7 (78.1, 91.5) 4.3 (4.7, 13.4)
Polymicrobial 171/202 84.7 (78.9, 89.3) 168/200 84.0 (78.2, 88.8) 0.7 (6.8, 8.2)
Overall
a Adjusted difference and its 95% CI are calculated from a generalized linear model with a binomial probability function and an iden
evaluable; c-mITT, clinically modified intent-to-treat (patients exhibiting clinical evidence of complicated intra-abdominal infectio
microbiological modified intent-to-treat (patients with a confirmed baseline isolate).
Table 3 Clinical cure rate by baseline diagnosis (Microbiologically Evaluable Population) at test-of-cure visit
Clinical diagnosis Tigecycline Imipenem/cilastatin
n/N % (95% CI) n/N % (95% CI)
Complicated appendicitis 104/111 93.7 (87.4, 97.4) 109/117 93.2 (87.0, 97.0)
Complicated diverticulitis 11/15 73.3 (44.9, 92.2) 12/17 70.6 (44.0, 89.7)
Complicated cholecystitis 56/57 98.2 (90.6, 100.0) 56/58 96.6 (88.1, 99.6)
Intra-abdominal abscess 29/34 85.3 (68.9, 95.0) 23/28 82.1 (63.1, 93.9)
Peritonitis 4/4 100.0 (39.8, 100.0) 3/4 75.0 (19.4, 99.4)
Gastric and duodenal
perforations
12/12 100.0 (73.5, 100.0) 13/15 86.7 (59.5, 98.3)
Perforations of the intestines 25/30 83.3 (65.3, 94.4) 14/17 82.4 (56.6, 96.2)
Other 1/2 50.0 (1.3, 98.7) 2/2 100.0 (15.8, 100.0)
Concomitant bacteremia 23/26 88.5 (69.8, 97.6) 20/23 87.0 (66.4, 97.2)
CI, confidence interval.
Tigecycline for complicated intra-abdominal infections 43T
a
b
le
4
M
ic
ro
b
io
lo
gi
c
re
sp
o
n
se
a
t
th
e
p
a
ti
e
n
t
le
ve
l
(M
ic
ro
b
io
lo
gi
ca
ll
y
E
va
lu
a
b
le
P
o
p
u
la
ti
o
n
)
a
t
te
st
-o
f-
cu
re
vi
si
t
R
e
sp
o
n
se
T
ig
e
cy
cl
in
e
Im
ip
e
n
e
m
/c
il
a
st
a
ti
n
D
if
fe
re
n
ce
(t
ig
e
cy
cl
in
e
e
im
ip
e
n
e
m
/
ci
la
st
a
ti
n
),
%
(9
5%
C
I)
T
e
st
fo
r
n
o
n
in
fe
ri
o
ri
ty
,
P
va
lu
e
T
e
st
fo
r
d
if
fe
re
n
ce
s
n
/N
%
(9
5%
C
I)
n
/N
%
(9
5%
C
I)
E
ra
d
ic
a
ti
o
n
24
2/
26
5
91
.3
(8
7.
3,
94
.4
)
23
2/
25
8
89
.9
(8
5.
6,
93
.3
)
1.
4
(
4.
0,
6.
8)
!
0.
00
01
0.
69
04
M
o
n
o
m
ic
ro
b
ia
l
86
/9
1
94
.5
(8
7.
6,
98
.2
)
83
/9
0
92
.2
(8
4.
6,
96
.8
)
2.
3
(
6.
3,
11
.1
)
P
o
ly
m
ic
ro
b
ia
l
15
6/
17
4
89
.7
(8
4.
1,
93
.8
)
14
9/
16
8
88
.7
(8
2.
9,
93
.1
)
1.
0
(
6.
1,
8.
2)
P
e
rs
is
te
n
ce
21
/2
65
7.
9
(5
.0
,
11
.9
)
26
/2
58
10
.1
(6
.7
,
14
.4
)
M
o
n
o
m
ic
ro
b
ia
l
5/
91
5.
5
(1
.8
,
12
.4
)
7/
90
7.
8
(3
.2
,
15
.4
)
P
o
ly
m
ic
ro
b
ia
l
16
/1
74
9.
2
(5
.3
,
14
.5
)
19
/1
68
11
.3
(6
.9
,
17
.1
)
Su
p
e
ri
n
fe
ct
io
n
2/
26
5
0.
8
(0
.1
,
2.
7)
0/
25
8
0.
0
(0
.0
,
1.
4)
M
o
n
o
m
ic
ro
b
ia
l
0/
91
0.
0
(0
.0
,
4.
0)
0/
90
0.
0
(0
.0
,
4.
0)
P
o
ly
m
ic
ro
b
ia
l
2/
17
4
1.
1
(0
.1
,
4.
1)
0/
16
8
0.
0
(0
.0
,
2.
2)
O
ve
ra
ll
1.
6
(
3.
3,
6.
4)
a
a
A
d
ju
st
e
d
d
if
fe
re
n
ce
a
n
d
it
s
95
%
co
n
fi
d
e
n
ce
in
te
rv
al
a
re
ca
lc
u
la
te
d
fr
o
m
a
ge
n
e
ra
li
ze
d
li
n
e
a
r
m
o
d
e
l
w
it
h
a
b
in
o
m
ia
l
p
ro
b
ab
il
it
y
fu
n
ct
io
n
a
n
d
a
n
id
e
n
ti
ty
li
n
k.The microbial eradication rates at the test-of-
cure visit for several selected isolates of clinical
interest were comparable between the 2 treatment
groups (Table 5). For E. coli, the most commonly
isolated aerobe, eradication rates were 91.7% for
tigecycline versus 91.1% for imipenem/cilastatin.
Eradication rates for Klebsiella pneumoniae, the
second most frequently isolated aerobe, were
also high (92.7% tigecycline versus 94.4% imipe-
nem/cilastatin). Tigecycline also appeared effec-
tive based on eradication/presumed eradication
rates against E. faecalis (non-vancomycin-resistant
enterococci [VRE]), as well as methicillin-sensitive
and -resistant S. aureus were eradicated at
ratesR 94% following tigecycline therapy. Eradica-
tion rates for Bacteroides fragilis were also similar
between the 2 treatment groups (86.4% tigecycline
versus 91.2% imipenem/cilastatin). Pretherapy in
vitro activity against these isolates for tigecycline
and imipenem/cilastatin are shown in Table 6.
Adverse events
Data from all patients in the mITT population were
analyzed for safety. The safety and tolerability of
tigecycline, including the frequency and distribu-
tion of adverse events, were similar to those of
imipenem/cilastatin. Regardless of study drug
causality, treatment-emergent adverse events oc-
curred in 60.4% (244 of 404) of tigecycline-treated
patients and 59.3% (245 of 413) of imipenem/
cilastatin-treated patients. The majority of these
adverse events was not related to study medica-
tion and was mild to moderate in intensity. The
frequency and distribution of the most common
treatment-emergent adverse events (i.e., occur-
ring in R3% of patients) for the tigecycline group
were similar to those observed after imipenem/
cilastatin therapy (Table 7). Nausea (17.5% tigecy-
cline, 13.3% imipenem/cilastatin; PZ 0.100) and
vomiting (12.6% tigecycline, 9.2% imipenem/cilas-
tatin; PZ 0.144) were the most frequently re-
ported adverse events in both groups. There was
no significant difference between the treatment
groups in the number of patients who required
antiemetic therapy for nausea and/or vomiting.
One hundred and eight (108) serious adverse
events were noted during the study (59 tigecycline
and 49 imipenem/cilastatin patients). The most
frequently reported serious adverse events were
abscess (nZ 13) and infection and abnormal heal-
ing (each, nZ 9) in tigecycline-treated patients,
compared with abscess (nZ 10) and local reaction
to a procedure (nZ 7) among imipenem/cilasta-
tin-treated patients.
44 P. Fomin et al.Table 5 Microbiologic response at the isolate level: selected baseline isolates at test-of-cure visit
(Microbiologically Evaluable Population)
Isolate Tigecycline Imipenem/cilastatin
n/N % (95% CI) n/N % (95% CI)
Bacteroides fragilis 38/44 86.4 (72.6, 94.8) 31/34 91.2 (76.3, 98.1)
Citrobacter spp. 11/13 84.6 (54.6, 98.1) 6/9 66.7 (29.9, 92.5)
Clostridium spp. 26/27 96.3 (81.0, 99.9) 23/26 88.5 (69.8, 97.6)
Enterobacter spp. 16/16 100.0 (79.4, 100.0) 12/12 100.0 (73.5, 100.0)
Enterococcus faecalis (non-VRE) 16/17 94.1 (71.3, 99.9) 26/29 89.7 (72.6, 97.8)
Escherichia coli 144/157 91.7 (86.3, 95.5) 144/158 91.1 (85.6, 95.1)
Fusobacterium spp. 6/6 100.0 (54.1, 100.0) 6/6 100.0 (54.1, 100.0)
Klebsiella spp. 38/41 92.7 (80.1, 98.5) 34/36 94.4 (81.3, 99.3)
Peptostreptococcus spp. 11/13 84.6 (54.6, 98.1) 11/13 84.6 (54.6, 98.1)
Staphylococcus aureus (MRSA) 3/3 100.0 (29.2, 100.0) 1/2 50.0 (1.3, 98.7)
S. aureus (non-MRSA) 18/19 94.7 (74.0, 99.9) 19/20 95.0 (75.1, 99.9)
Veillonella spp. 7/7 100.0 (59.0, 100.0) 3/3 100.0 (29.2, 100.0)
Proteus spp. 7/9 77.8 (40.0, 97.2) 11/15 73.3 (44.9, 92.2)
Pseudomonas aeruginosa 19/21 90.5 (69.6, 98.8) 12/15 80.0 (51.9, 95.7)
CIZ confidence interval; MRSAZmethicillin-resistant Staphylococcus aureus; VREZ vancomycin-resistant enterococci.Adverse events were the primary reason for
early withdrawal of study drug (19 [4.7%] tigecy-
cline-treated and 21 [5.1%] imipenem/cilastatin-
treated patients). Seven tigecycline patients
discontinued treatment because of vomiting,
whereas 6 impenem/cilastatin-treated patients
discontinued treatment secondary to nausea.
There were no significant differences between
treatment groups in any single adverse event
leading to the discontinuation of study drug.
Twelve patients died during the study: 7 pa-
tients in the tigecycline treatment group and 5 in
the imipenem/cilastatin treatment group. None of
the deaths was considered by the investigators to
be related to study drug.
No clinically important or unexpected changes
in any routine hematologic or serum chemistrytests, vital signs, or ECG data were associated with
the use of tigecycline or impenem/cilastatin.
However, significantly more patients treated with
tigecycline had increased amylase (P! 0.01) and
increased BUN values (P! 0.001). The reported
amylase elevations in the tigecycline group were
mild and not associated with pancreatitis, nausea,
or vomiting. Furthermore, the increased BUN
values were not associated with increases in serum
creatinine. No significant changes in QTc interval
were observed in either treatment group.
Discussion
Rising rates of antibiotic resistance, especially in
the hospital setting, have heightened the needTable 6 Minimal Inhibitory Concentration (MIC) Range, and MIC50 and MIC90 values, of selected primary baseline
isolates (Microbiologically Evaluable Population)
Isolate n Tigecycline Imipenem/cilastatin
MIC range MIC50 MIC90 MIC range MIC50 MIC90
Bacteroides fragilis 78 0.12e16.0 0.5 2.0 0.12e1.0 0.12 0.50
Clostridium spp. 1 0.06e0.06 NA NA 0.25e0.25 NA NA
Enterococcus faecalis (non-VRE) 46 0.06e1.0 0.25 0.25 0.50e8.0 2.0 4.0
Escherichia coli 315 0.06e1.0 0.25 0.50 0.12e1.0 0.12 0.25
Fusobacterium spp. 2 0.12e0.25 NA NA 0.12e0.50 NA NA
Staphylococcus aureus (MRSA) 5 0.12e0.25 NA NA 0.12e32.0 NA NA
S. aureus (non-MRSA) 39 0.06e0.50 0.12 0.25 0.12e4.0 0.12 0.12
Veillonella spp. 10 0.12e1.0 0.25 1.0 0.12e0.12 0.12 0.12
Pseudomonas aeruginosa 36 4.0e32.0 16.0 16.0 0.50e16.0 1.0 8.0
NAZ MIC50 and MIC90 values are not valid if the number of isolates is less than 10; MRSAZmethicillin-resistant Staphylococcus
aureus; VREZ vancomycin-resistant enterococci.
Tigecycline for complicated intra-abdominal infections 45to develop new antimicrobial therapies for
the treatment of complicated intra-abdominal
infections.16,17 Tigecycline is a first-in-class glycyl-
cycline antibiotic that has expanded broad-spec-
trum in vitro activity against common aerobic
and anaerobic isolates found in intra-abdominal
infections, including coverage against resistant
isolates.7e15 In this phase 3 trial, the efficacy
and safety of tigecycline monotherapy for the
treatment of complicated intra-abdominal infec-
tions were compared with imipenem/cilastatin,
which is a commonly recommended antibiotic
therapy.1,18,19 The main finding of this large phase
3 trial is that tigecycline (50 mg infusion every 12 h
after an initial dose of 100 mg) was efficacious and
statistically noninferior to imipenem/cilastatin
(500 mg/500 mg every 6 h), as observed in prede-
fined patient populations (m-mITT and ME) at the
test-of-cure visit. Notably, these findings were
Table 7 Common treatment-emergent adverse
eventsa
Body system
adverse event
Tigecycline
(NZ 404)
Imipenem/
cilastatin
(NZ 413)
Any adverse event 244 (60.4) 245 (59.3)
Body as a whole 109 (27.0) 101 (24.5)
Abdominal pain 15 (3.7) 14 (3.4)
Asthenia 15 (3.7) 10 (2.4)
Fever 18 (4.5) 30 (7.3)
Headache 9 (2.2 18 (4.4)
Infectionb 27 (6.7) 14 (3.4)
Cardiovascular system 41 (10.1) 49 (11.9)
Hypertension 16 (4.0) 13 (3.1)
Digestive system 128 (31.7) 120 (29.1)
Diarrhea 25 (6.2) 31 (7.5)
Nausea 71 (17.6) 55 (13.3)
Vomiting 51 (12.6) 38 (9.2)
Hemic and lymphatic system 50 (12.4) 50 (12.1)
Anemia 17 (4.2) 19 (4.6)
Thrombocythemia 23 (5.7) 25 (6.1)
Metabolic and nutritional 77 (19.1) 68 (16.5)
Amylase increased 15 (3.7) 4 (1.0)
Hypoproteinemia 15 (3.7) 13 (3.1)
Lactic dehydrogenase
increased
16 (4.0) 14 (3.4)
AST/SGOT 10 (2.5) 13 (3.1)
Local reaction to procedure 28 (6.9) 27 (6.5)
AST/SGOTZ aspartate aminotransferase/serum glutamic
oxaloacetic transaminase.
a Defined as those occurring in R3% of patients.
b Significant between-group difference at 0.05 level.consistent across different types of infection and
against the broad array of bacterial species en-
countered.
Tigecycline was effective at eradicating the
most common aerobic and anaerobic bacteria
implicated in complicated intra-abdominal infec-
tions, with overall eradication rates exceeding
90%. In addition to E. coli and K. pneumoniae
(the most frequently recovered isolates overall),
tigecycline also was effective at eradicating or-
ganisms that typically convey resistance, including
E. faecalis (non-VRE) and methicillin-sensitive and
-resistant S. aureus (allR 90%). The effectiveness
of tigecycline against difficult-to-treat gram-
positive organisms is also encouraging (e.g.,
MIC90% 0.25 mg/L against methicillin-resistant
S. aureus), despite the fact that few resistant
isolates were identified. Emergence of tigecycline
resistance during therapy was not observed.
Clinical trial data from phase 1 and phase 2
studies suggest that IV tigecycline is well tolera-
ted.20e25 The results of the current trial are consis-
tent with earlier findings and demonstrated that
both tigecycline and imipenem/cilastatin were
generally well tolerated with similar rates of treat-
ment-emergent adverse events. Nausea and vomit-
ing were the most frequently reported adverse
events in both treatment groups, with slightly
higher rates reported after tigecycline therapy.
There also was no evidence of clinically significant
changes following routine serum chemistry and
hematology testing.
The effectiveness of tigecycline demonstrated
in this large phase 3 trial extends the findings of
a phase 2 tigecycline trial in 66 hospitalized
patients with predominantly perforated appendi-
citis.23 The validity of the current trial is also
evident in that the response rates after imipenem/
cilastatin therapy were similar to the findings of
several published studies in which imipenem/
cilastatin had similar cure rates compared with
either meropenem, ciprofloxacin, piperacillin/
tazobactam, or gentamicin/clindamycin.26e29
Conclusion
The findings reported herein, coupled with the
increasing need for antibiotics with improved
activity against resistant isolates, suggest that
tigecycline is a promising new monotherapy for
the treatment of complicated intra-abdominal
infections where empiric coverage is needed
against both gram-positive and gram-negative
bacteria.
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